NASDAQ: RTSN
Retension Pharmaceuticals Inc Earnings Dates, Reports, Calls

Retension Pharmaceuticals earnings were N/A for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest RTSN earnings report on Jun 30, 2026 announced Q2 2026 earnings of N/A, down N/A from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, RTSN reported annual earnings of -$6.3M, with 230% growth.

RTSN earnings history

Current Revenue
$0.0
Current Earnings
$0.0
Current Profit Margin
0%

RTSN Return on Equity

Insufficient data to display

RTSN Return on Assets

Insufficient data to display

Be the first to know when RTSN announces earnings.

RTSN Return on Capital Employed

Current Company
0%
Current Industry
-7.4%

RTSN vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
AARD-$69.51M-$69.89MN/A-$3.21
ABVC-$6.46M-$7.11MN/A-$0.29
ABVX-$285.22M-$460.11MN/A-$5.96
ACET-$89.96M-$98.97MN/A-$10.46
TRXBN/AN/AN/AN/A

Retension Pharmaceuticals Earnings Reports & History FAQ

What was RTSN's earnings growth in the past year?

As of Retension Pharmaceuticals's earnings date in Q4 2026, Retension Pharmaceuticals's earnings has grown year over year. RTSN earnings in the past year totalled N/A.

If you're new to stock investing, here's how to buy Retension Pharmaceuticals stock.

Is Retension Pharmaceuticals profitable or losing money?

As of the last Retension Pharmaceuticals earnings report, Retension Pharmaceuticals is currently losing money. Retension Pharmaceuticals's net profit (also called net income) for the twelve months ending Jun 30, 2026 was N/A, a N/A decrease year over year.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.